Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-MEDY
2005-002536-94Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) comparing Dabigatran etexilate with Warfarin (2 arms). Started Feb 2006; status: completed.
02
Drugs
dabigatranwarfarin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2005-002536-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002536-94.